- Home
- FFC vs SLN Comparison
FFC vs SLN Comparison
Compare FFC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFC | SLN |
|---|---|---|
| Founded | 1983 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.8M | 236.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FFC | SLN |
|---|---|---|
| Price | $15.61 | $5.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 148.4K | ★ 345.9K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 6.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.20 | $1.97 |
| 52 Week High | $17.00 | $7.91 |
Technical Indicators
Market Signals| Indicator | FFC | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 53.12 |
| Support Level | N/A | $5.79 |
| Resistance Level | $16.84 | $6.19 |
| Average True Range (ATR) | 0.22 | 0.58 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 60.38 | 37.66 |
Price Performance
Historical ComparisonAbout FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.